dwinnex.com

Intuitive Surgical, Inc. [NASDAQ:ISRG]: Analyst Rating and Earnings

Experts stock market traders frequently make a point to check what top Wall Street analysts say regarding a potential buy. Regarding Intuitive Surgical, Inc. [ISRG] currently, the latest Wall Street ratings we can see is from the fiscal quarter that’s going to end in December. On average, stock market experts give ISRG an Outperform rating. The average 12-month price forecast for this stock is $579.41, with the high estimate being $635.00, the low estimate being $300.00 and the median estimate amounting to $610.00. This is compared to its latest closing price of $517.11.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Intuitive Surgical, Inc. [ISRG] is sitting at 2.00. This is compared to 1 month ago, when its average rating was 2.00.

For the quarter ending in Sep-18 Intuitive Surgical, Inc. [ISRG] generated $0.92 billion in sales. That’s 0.42% higher than the average estimate of $0.92 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.

Stay on the lookout for the next publication of this organization’s financial results for the quarter, which will be made public on Thu 24 Jan (In 13 Days).

Fundamental Analysis of Intuitive Surgical, Inc. [ISRG]

Now let’s turn to look at profitability: with a current Operating Margin for Intuitive Surgical, Inc. [ISRG] sitting at +34.57 and its Gross Margin at +69.91, this company’s Net Margin is now 22.30%. These measurements indicate that Intuitive Surgical, Inc. [ISRG] is generating considerably more profit, after expenses are accounted for, compared to its market peers.

This company’s Return on Total Capital is 20.62, and its Return on Invested Capital has reached 19.60%. Its Return on Equity is 12.57, and its Return on Assets is 10.78. These metrics show a mixed bag, which means that this investment’s attractiveness can be quickly increased or decreased in the short term, depending on future updates ISRG financial performance.

What about valuation? This company’s Enterprise Value to EBITDA is 44.07. The Enterprise Value to Sales for this firm is now 14.54. Intuitive Surgical, Inc. [ISRG] has a Price to Book Ratio of 8.67, a Price to Cash Flow Ratio of 37.10 and P/E Ratio of 77.44. These metrics suggest that this publicly-traded organization will not likely result in investment gains.

Shifting the focus to workforce efficiency, Intuitive Surgical, Inc. [ISRG] earns $704,725 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 6.18 and its Total Asset Turnover is 0.51. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 3.65 and its Current Ratio is 3.99. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Performance Indicators

Let’s now turn our attention to trading performance: Intuitive Surgical, Inc. [ISRG] has 114.00M shares outstanding, amounting to a total market cap of $59.06B. Its stock price has been found in the range of 380.00 to 581.12. At its current price, it has moved by -10.85% from its 52-week high, and it has moved 36.33% from its 52-week low.

This stock’s Beta value is currently 1.17, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 58.67. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Intuitive Surgical, Inc. [ISRG] a Reliable Buy?

Shares of Intuitive Surgical, Inc. [ISRG], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.